智通财经APP获悉，在诺和诺德(NVO.US)终止与远程医疗公司Hims & Hers Health合作后，摩根士丹利发布研报给予Hims & Hers ...

在诺和诺德 (NVO.US)终止与远程医疗公司Hims & Hers Health合作后，摩根士丹利发布研报给予 Hims & Hers Health (HIMS.US)“与大盘持平”评级，最新目标价40美元。

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

摩根士丹利 分析师在研报中指出，Hims & Hers Health面临的核心问题在于，若 诺和诺德 对其发起诉讼，该公司能否继续提供复合式GLP-1药物疗法。

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Senate To Begin Marathon Vote Series On Trump's "Big, Beautiful Bill" As GOP Eyes July 4 Deadline The Senate is set to kick off what's expected to be a marathon session Monday, after the chamber ...

Weight Watchers is Novo Nordisk's latest partnersip.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

出品 | 虎嗅科技医疗组 作者 | 陈广晶 编辑 | 苗正卿 头图 | AI生成 诺和诺德导演了一场双输的剧情。 就在6月23日，丹麦制药巨头诺和诺德忽然宣布解除与知名远程医疗平台hims&hers ...

As GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...